tradingkey.logo
tradingkey.logo
Search

Caris Life Sciences Inc

CAI
Add to Watchlist
17.820USD
-0.500-2.73%
Close 06/30, 16:00ETQuotes delayed by 15 min
5.04BMarket Cap
LossP/E TTM

Caris Life Sciences Inc

17.820
-0.500-2.73%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

-2.73%

5 Days

+2.95%

1 Month

+6.58%

6 Months

-34.77%

Year to Date

-33.95%

1 Year

-33.53%

Key Figures
18.300Open
18.585High
3.76MVolume
LossP/E TTM
48.57P/E Dynamic
--Dividend TTM
1.33%Turnover Ratio
18.320Prev. Close
17.500Low
54.58MTurnover
LossP/E Static
8.49P/B
0.00%Div Yield TTM
4.67%ROA
42.50052wk High
0.94Volume Ratio
-378.26MNet Profit
282.65MShares
-2.7620EPS TTM
--Beta
--ROE
16.28052wk Low
5.92%Amplitude
65.39%Gross Margin
5.04BMarket Cap
2.97Reward/Risk
3.83%Risk Rate

Key Insights

Caris Life Sciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 78 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.33.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caris Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
78 / 204
Overall Ranking
184 / 4570
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Caris Life Sciences Inc Highlights

StrengthsRisks
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 165.26% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 812.03M.
Undervalued
The company’s latest PE is -6.63, at a low 3-year percentile range.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 2.20M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
28.333
Target Price
+54.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Caris Life Sciences Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Caris Life Sciences Inc Info

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Ticker SymbolCAI
CompanyCaris Life Sciences Inc
CEOHalbert (David Dean)
Websitehttps://www.carislifesciences.com/

FAQs

What is the current price of Caris Life Sciences Inc (CAI)?

The current price of Caris Life Sciences Inc (CAI) is 18.32.

What is the symbol of Caris Life Sciences Inc?

The ticker symbol of Caris Life Sciences Inc is CAI.

What is the 52-week high of Caris Life Sciences Inc?

The 52-week high of Caris Life Sciences Inc is 42.50.

What is the 52-week low of Caris Life Sciences Inc?

The 52-week low of Caris Life Sciences Inc is 16.28.

What is the market capitalization of Caris Life Sciences Inc?

The market capitalization of Caris Life Sciences Inc is 5.23B.

Is Caris Life Sciences Inc (CAI) currently rated as Buy, Hold, or Sell?

According to analysts, Caris Life Sciences Inc (CAI) has an overall rating of Buy, with a price target of 28.33.

What is the Earnings Per Share (EPS TTM) of Caris Life Sciences Inc (CAI)?

The Earnings Per Share (EPS TTM) of Caris Life Sciences Inc (CAI) is -3.22.
KeyAI